Defining the role of panitumumab in colorectal cancer

Community Oncology

Volumn 3, Issue 10 SUPPL. 4, 2006, Pages

  Grothey, Axel ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MATUZUMAB; OXALIPLATIN; PANITUMUMAB; VECTIBIX;

ADD ON THERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HYPOMAGNESEMIA; INFUSION REACTION; LOADING DRUG DOSE; METASTASIS; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 33845605751     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Fuchs C, Marshall J, Mitchell E, et al. A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). J Clin Oncol 2006;24(18S):3506.
2. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropynmidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-study. J Clin Oncol 2006;24(18S):3510.
3. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorm, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorm tor metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
6. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 2002;7(suppl 4):2-8.
7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
8. Saltz LB, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001;20:7.
9. Saltz LB, Meropol NJ, Loehrer P, et al. Single agent IMC-C225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002;21:504.
10. Lenz HJ, Mayer RJ, Mirtsching B, et al. Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2005;23(16S):3536.
11. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity m colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810.
12. Tejpar S, Peeters M, Humblet Y, et al. Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): preliminary data. J Clin Oncol 2006;24(18S):3554.
13. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
14. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-2069.
15. Diaz Rubio E, Tabernero J, van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. J Clin Oncol 2005;25(16S):3535.
16. Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcmoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 2006;24(18S):3509.
17. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23.
18. Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2005;23(16S):3520.
19. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr). J Clin Oncol 2006;24(18S):3548.
20. Hecht J, Mitchell E, Baranda J, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (< 1%) levels ot epidermal growth factor receptor (EGFr). J Clin Oncol 2006;24(18S):3547.
21. th Annual Meeting of the American Association for Cancer Research; April 1-5, 2006; Washington, DC. Abstract CP-1.
22. Erbitux [package insert]. Branchburg, NJ: ImClone Systems Inc/Princeton, NJ: Bristol-Myers Squibb Co; 2006.
23. Vectibix [package insert]. Thousand Oaks, Calif: Amgen Inc; 2006.
24. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22:3003-3015.
25. Tabernero J, Cervantes A, Martinelli E, et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2006;24(18S):3085.
26. Hecht J, Posey J, Tchekmedyian S, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIR1 for first-line treatment of metastatic colorectal cancer (mCRC). Paper presented at the 2006 Gastrointestinal Cancers Symposium; January 26-28, 2006; San Francisco, Calif. Abstract 237.
27. Schrag D, Chung KY, Flombaum C, et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005;97:1221-1224.